Circulating Inflammatory Proteins Are Elevated in Type 1 and Type 2 Diabetes and Associated to Complications

Overview

Journal Diabetes Obes Metab

Specialty Endocrinology

Date 2024 Nov 19

PMID 39562286

Authors

Julia I P van Heck

Mandala Ajie

Leo A B Joosten

Cees J Tack

Rinke Stienstra

Affiliations

Soon will be listed here.

Abstract

Background: The presence of low-grade inflammation has been reported in people with type 2 diabetes and related to the development of (macro)vascular complications. Whether systemic inflammation is present in type 1 diabetes and linked to long-term complications remains unknown. We used a targeted proteomics approach to compare inflammation in people with type 1 diabetes and type 2 diabetes with control subjects and linked these proteins to diabetes related characteristics and complications.

Methods: We included 233 participants with type 1 diabetes, 387 participants with type 2 diabetes and 150 healthy controls. Plasma was collected and used to determine high sensitive C-reactive proteins (hs-CRP) and an additional 92 inflammatory proteins using the Olink proteomics platform.

Results: Compared to healthy controls, 41 circulating inflammatory proteins were higher in type 1 diabetes (FDR < 0.05) and 64 inflammatory proteins in type 2 diabetes (FDR < 0.05) (including CXCL5, IL-15RA, MCP-4 and AXIN1 for both groups). HbA levels were positively associated with 21 inflammatory proteins (including CDCP1, FGF-21, HGF and IL-18R1) in type 1 diabetes (FDR < 0.05), whereas a positive association existed between body mass index (BMI) and 26 inflammatory proteins (including IL6, IL17C, FGF-23 and CSF-1) in type 2 diabetes. Inflammatory proteins associated with the presences, of complications, particularly nephropathy, were similar in both type 1 and type 2 diabetes. FlT3L and EN-RAGE were associated with the development of cardiovascular disease (CVD) in type 2 diabetes.

Conclusions: Both type 1 diabetes and type 2 diabetes are associated with increased circulating inflammatory protein concentrations, but the increase is more pronounced in type 2 diabetes. These results suggest both differences in drivers of inflammation between type 1 diabetes and type 2 diabetes as well as potential similarities in pathways involved in the development of diabetes-associated complications.

Citing Articles

Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications.

van Heck J, Ajie M, Joosten L, Tack C, Stienstra R Diabetes Obes Metab. 2024; 27(2):719-728.

PMID: 39562286 PMC: 11701194. DOI: 10.1111/dom.16066.

References

Schalkwijk C, Poland D, van Dijk W, Kok A, Emeis J, Drager A . Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999; 42(3):351-7. DOI: 10.1007/s001250051162. View

van Heck J, Ajie M, Joosten L, Tack C, Stienstra R . Circulating inflammatory proteins are elevated in type 1 and type 2 diabetes and associated to complications. Diabetes Obes Metab. 2024; 27(2):719-728. PMC: 11701194. DOI: 10.1111/dom.16066. View

Hofmann M, Drury S, Fu C, Qu W, Taguchi A, Lu Y . RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999; 97(7):889-901. DOI: 10.1016/s0092-8674(00)80801-6. View

Lu X, Rudemiller N, Privratsky J, Ren J, Wen Y, Griffiths R . Classical Dendritic Cells Mediate Hypertension by Promoting Renal Oxidative Stress and Fluid Retention. Hypertension. 2019; 75(1):131-138. PMC: 7004279. DOI: 10.1161/HYPERTENSIONAHA.119.13667. View

Chavey C, Lazennec G, Lagarrigue S, Clape C, Iankova I, Teyssier J . CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab. 2009; 9(4):339-49. PMC: 2804846. DOI: 10.1016/j.cmet.2009.03.002. View

Zernecke A . Dendritic cells in atherosclerosis: evidence in mice and humans. Arterioscler Thromb Vasc Biol. 2015; 35(4):763-70. DOI: 10.1161/ATVBAHA.114.303566. View

Pfutzner A, Forst T . High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther. 2006; 8(1):28-36. DOI: 10.1089/dia.2006.8.28. View

S Ellulu M, Patimah I, Khazaai H, Rahmat A, Abed Y . Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017; 13(4):851-863. PMC: 5507106. DOI: 10.5114/aoms.2016.58928. View

Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I . Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006; 55(3):774-9. DOI: 10.2337/diabetes.55.03.06.db05-1417. View

10.

Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen S, Ekman D . Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 2014; 9(4):e95192. PMC: 3995906. DOI: 10.1371/journal.pone.0095192. View

11.

Prattichizzo F, de Candia P, Ceriello A . Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism. 2021; 120:154799. DOI: 10.1016/j.metabol.2021.154799. View

12.

Pai J, Pischon T, Ma J, Manson J, Hankinson S, Joshipura K . Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351(25):2599-610. DOI: 10.1056/NEJMoa040967. View

13.

Nunemaker C, Chung H, Verrilli G, Corbin K, Upadhye A, Sharma P . Increased serum CXCL1 and CXCL5 are linked to obesity, hyperglycemia, and impaired islet function. J Endocrinol. 2014; 222(2):267-76. PMC: 4135511. DOI: 10.1530/JOE-14-0126. View

14.

Zatterale F, Longo M, Naderi J, Raciti G, Desiderio A, Miele C . Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020; 10:1607. PMC: 7000657. DOI: 10.3389/fphys.2019.01607. View

15.

Crook M, Tutt P, Simpson H, Pickup J . Serum sialic acid and acute phase proteins in type 1 and type 2 diabetes mellitus. Clin Chim Acta. 1993; 219(1-2):131-8. DOI: 10.1016/0009-8981(93)90204-h. View

16.

Bermudez E, Rifai N, Buring J, Manson J, Ridker P . Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol. 2002; 22(10):1668-73. DOI: 10.1161/01.atv.0000029781.31325.66. View

17.

Ryan A, Nicklas B . Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care. 2004; 27(7):1699-705. DOI: 10.2337/diacare.27.7.1699. View

18.

Calle M, Fernandez M . Inflammation and type 2 diabetes. Diabetes Metab. 2012; 38(3):183-91. DOI: 10.1016/j.diabet.2011.11.006. View

19.

Rodriguez-Moran M, Guerrero-Romero F . Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. J Diabetes Complications. 2000; 13(4):211-5. DOI: 10.1016/s1056-8727(99)00047-1. View

20.

Chen Y, Qiao Y, Pan Y, Xu Y, Huang Y, Wang Y . Correlation between serum interleukin-6 level and type 1 diabetes mellitus: A systematic review and meta-analysis. Cytokine. 2017; 94:14-20. DOI: 10.1016/j.cyto.2017.01.002. View